Gapping down
In reaction to disappointing earnings/guidance: LITB -4.2%, POZN -4.2%, MCD -1.2%, (reports Feb global comps -1.7%; -4% in the US) BITA -0.7%
M&A news: AA -2% (Alcoa to acquire RTI for $41/share in a stock for stock)
Other news: ACRX -42.8% (provides update on the timing and potential content of the resubmission of the New Drug Application for Zalviso; receives correspondence from the FDA that an additional clinical study is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures), NBG -7.7% (EU Pres comments regarding Greece reform proposals), IBN -2.9% (Sensex down over 2% overnight), RDY -0.8% (Sensex down over 2% overnight)
Analyst comments: BBRY -3.9% (downgraded to Sell from Neutral at Goldman), CLF -1.6% (downgraded to Sell from Hold at Axiom Capital), KORS -1.6% (cautious comments and target lowered to $72 from $76 at Sterne Agee), TSM -1.5% (downgraded to Underperform from Sector Perform at Pacific Crest), LAZ -0.9% (downgraded to Neutral from Positive at Susquehanna), LEN -0.7% (downgraded to Neutral from Buy at Buckingham Research)
In reaction to disappointing earnings/guidance: LITB -4.2%, POZN -4.2%, MCD -1.2%, (reports Feb global comps -1.7%; -4% in the US) BITA -0.7%
M&A news: AA -2% (Alcoa to acquire RTI for $41/share in a stock for stock)
Other news: ACRX -42.8% (provides update on the timing and potential content of the resubmission of the New Drug Application for Zalviso; receives correspondence from the FDA that an additional clinical study is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures), NBG -7.7% (EU Pres comments regarding Greece reform proposals), IBN -2.9% (Sensex down over 2% overnight), RDY -0.8% (Sensex down over 2% overnight)
Analyst comments: BBRY -3.9% (downgraded to Sell from Neutral at Goldman), CLF -1.6% (downgraded to Sell from Hold at Axiom Capital), KORS -1.6% (cautious comments and target lowered to $72 from $76 at Sterne Agee), TSM -1.5% (downgraded to Underperform from Sector Perform at Pacific Crest), LAZ -0.9% (downgraded to Neutral from Positive at Susquehanna), LEN -0.7% (downgraded to Neutral from Buy at Buckingham Research)